Anebulo Pharmaceuticals, Inc. (ANEB)

Market Cap	69.02M
Revenue (ttm)	n/a
Net Income (ttm)	-7.69M
Shares Out	41.08M
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,666
Open	1.810
Previous Close	1.810
Day's Range	1.680 - 1.810
52-Week Range	0.800 - 3.080
Beta	-1.16
Analysts	Strong Buy
Price Target	5.50 (+227.38%)
Earnings Date	May 13, 2025

About ANEB

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 7, 2021
• Employees: 3
• Stock Exchange: NASDAQ
• Ticker Symbol: ANEB
• Website: https://www.anebulo.com

Analyst Summary

According to 2 analysts, the average rating for ANEB stock is "Strong Buy." The 12-month stock price target is $5.5, which is an increase of 227.38% from the latest price.

Price Target

$5.5

(227.38% upside)

Analyst Consensus: Strong Buy